Home › Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
 

Keywords :   


Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

2014-04-02 06:18:01| drugdiscoveryonline News Articles

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio® (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe VOD or sVOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy

Tags: commercial treatment approved european

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05Estée Lauder Companies Presents Research at the Society for Investigative Dermatology Annual ...
21.05Dove Launches Whole Body Deodorants for 72-Hour Odor Protection
21.05Drowsy Sleep Co Launches Eyelash Protecting Mask
21.05Growth Opportunities in Upcycled Ingredients Anticipated Through 2032
21.05Superior Environmental Solutions Acquires Arrowhead Environmental Services
21.05Kinderhook Partners with Apex Waste Solutions and Acquires Materials Management Company and All American Disposal
21.05Liebherr Appoints Hobgood as New GM of Corporate Responsibility and Sustainability
21.05Tennessee Recycling Center Closing Due to Continued Dumping of Un-Recyclable Materials
More »